Please ensure Javascript is enabled for purposes of website accessibility

Amgen Blows Past EPS Estimates for the Second Quarter

By Eric Volkman – Jul 29, 2020 at 10:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech delivered growth on both the top and bottom lines despite the COVID-19 pandemic.

What coronavirus? Amgen's (AMGN -1.32%) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors.

The veteran biotech company booked revenue of nearly $6.21 billion in the second quarter, 6% higher on a year-over-year basis. Non-GAAP (adjusted) net profit rose by 4% to nearly $2.6 billion, or $4.25 per share.

Both of those line items topped analysts' consensus expectations. On average, prognosticators following the company were modeling for $6.18 billion on the top line, and an adjusted net profit of $3.84 per share.

A doctor making a consultation.

Image source: Getty Images.

Amgen has a sizable portfolio of medications. Due to coronavirus-related challenges -- the lack of in-person sales meetings and the concentration of healthcare resources on the pandemic, among numerous others -- the sales figures for most of its products fell during the quarter.

Yet the gains and additions posted by some of Amgen's smaller and newer treatments -- notably the psoriasis drug Otezla, purchased last year from Celgene -- more than compensated for the declines elsewhere in the portfolio.

Management also proffered guidance for the entirety of 2020. The company reiterated its existing estimate for total revenue in the range of $25 billion to $25.6 billion, and increased its adjusted EPS forecast range to $15.10 to $15.75 -- previously, it was $14.85 to $15.60. Capital expenditures should come in at roughly $600 million for the year.

As for shareholder returns, the company said share repurchases "will be executed opportunistically," in a volume at the bottom end of its prior guidance for stock buybacks in the range of $3 billion to $5 billion. The quarterly dividend should be maintained at $1.60 per share, which yields 2.5% at the most recent closing stock price.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
$225.40 (-1.32%) $-3.01
Celgene Corporation Stock Quote
Celgene Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.